beta Lactamase Inhibitor Drug Class List

Drugs in Drug Class: beta Lactamase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-002	Feb 24, 1998		RX	Yes	Yes
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-003	Feb 24, 1998		RX	Yes	Yes
Baxter Hlthcare Corp	ZOSYN IN PLASTIC CONTAINER	piperacillin sodium; tazobactam sodium	INJECTABLE;INJECTION	050750-001	Feb 24, 1998		RX	Yes	Yes
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	10,125,149		Y
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	8,685,957			Y
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	8,906,898		Y	Y
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	8,968,753

Beta Lactamase Inhibitor Market Analysis and Financial Projection

The beta-lactamase inhibitor market is experiencing significant growth driven by rising antibiotic resistance and technological advancements, while the patent landscape reflects intense innovation to combat evolving bacterial mechanisms. Here's a comprehensive analysis:

Market Dynamics

Projected Growth

• The market is expected to grow from $28.76 billion (2023) to $34.77 billion by 2032 (2.4% CAGR)[5], with estimates reaching $36.04 billion by 2030 (4.71% CAGR)[8], driven by demand in LMICs and infectious disease burden.
• Technavio forecasts a $8.4 billion expansion (2025–2029) at 4.7% CAGR, emphasizing AI-driven drug discovery and high-throughput screening[1][4].

Market Aspect	Key Insight	Source
Growth Driver	AI-powered high-throughput screening reduces drug discovery time by 60%	[1][4]
Key Challenge	Carbapenem-resistant Enterobacteriaceae (CRE) reduces treatment efficacy by 40%	[1][4]
Regional Leader	North America holds 39% market share due to advanced healthcare infrastructure	[4][8]

Technological Advancements

• AI and genomics enable rapid identification of novel compounds and resistance mechanisms, accelerating inhibitor development[1][4].
• Microfluidic platforms reduce screening costs by 30% while increasing throughput by 5x[1].

Market Constraints

• Antibiotic misuse fuels resistance, rendering 50% of traditional beta-lactams ineffective in some regions[5][10].
• Regulatory hurdles delay drug approvals by 2–3 years, costing $2.6 billion per approved therapy[12].

Patent Landscape

Innovation Trends

• Recent patents focus on metallo-beta-lactamase inhibitors (e.g., EP3654968B1) and broad-spectrum combos like ceftazidime-avibactam[3][13].
• Key Patent Developments:
  • US8487093B2: Dual-action inhibitors effective against Class A/C enzymes[2].
  • US10351525B2: Bismuth-based compounds showing 95% MBL inhibition in trials[13].

Competitive R&D

• Pfizer and Merck lead with 12% of pipeline drugs in Phase III trials targeting multidrug-resistant pathogens[9].
• Asia-Pacific dominates patent filings (38%), driven by China’s $1.2B antibiotic research initiative[9][10].

Strategic Opportunities

• Combination Therapies: Penicillin/beta-lactamase inhibitor combos account for 45% of late-stage trials[10].
• Patent Expirations: RECARBRIO’s key patents expire between 2025–2027, creating a $1.8B generic opportunity[11].

Emerging Threats

• Novel resistance mechanisms evolve faster than drug development cycles, requiring $4B annual R&D investment to maintain efficacy[6][12].

Regional Insights

• Asia-Pacific: Projected 6.1% CAGR (2025–2030) due to unregulated antibiotic sales and 580M annual infectious disease cases[5][10].
• Europe: Strict antimicrobial stewardship policies reduce antibiotic use by 15% but drive premium pricing for new inhibitors[8][12].

“The integration of AI in beta-lactamase inhibitor discovery has shortened development timelines from 10 years to 6.5 years” – Technavio 2025 Market Report[1].

This evolving landscape underscores the critical balance between innovation acceleration and resistance mitigation, with next-gen inhibitors like avibactam derivatives poised to capture 22% of the market by 2029[7][12].

References

1. https://www.prnewswire.com/news-releases/beta-lactam-and-beta-lactamase-inhibitors-market-to-grow-by-usd-8-4-billion-from-2025-2029--driven-by-novel-drug-development-with-ai-driving-market-transformation---technavio-302351420.html
2. https://patents.google.com/patent/US8487093B2/en
3. https://data.epo.org/publication-server/rest/v1.0/publication-dates/20230816/patents/EP3654968NWB1/document.pdf
4. https://www.medindia.net/health-press-release/beta-lactam-and-beta-lactamase-inhibitors-market-to-grow-by-usd-84-billion-from-2025-2029-driven-by-novel--701364-1.htm
5. https://www.zionmarketresearch.com/report/beta-lactam-and-beta-lactamase-inhibitors-market
6. https://pubs.acs.org/doi/10.1021/acsinfecdis.2c00485
7. https://www.giiresearch.com/report/infi1626446-global-beta-lactam-beta-lactamase-inhibitors.html
8. https://www.360iresearch.com/library/intelligence/beta-lactam-beta-lactamase-inhibitors
9. https://synapse.patsnap.com/blog/analysis-on-the-clinical-research-progress-of-b-lactamase-inhibitor
10. https://www.alliedmarketresearch.com/beta-lactam-and-beta-lactamase-inhibitors-market
11. https://www.drugpatentwatch.com/p/tradename/RECARBRIO
12. https://www.researchandmarkets.com/reports/5715533/beta-lactam-and-beta-lactamase-inhibitors-market
13. https://patents.google.com/patent/US10351525B2/en